Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.

The British journal of dermatology - 1 Sept 2018

Moreira A, Kirchberger M C, Toussaint F, Erdmann M, Schuler G, Heinzerling L

Abstract excerpt

We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Basal Cell Nevus Syndrome

Share to Infusions, Intravenous

Share to Programmed Cell Death 1 Receptor

Share to Repressor Proteins

Share to Skin Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 29603722
DOI: 10.1111/bjd.16607

Genes

SUFU

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.PMID 29603722Read ↗

Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms InvolvedSemantic proximity Read ↗

Acquisition of drug resistance in basal cell nevus syndrome tumors through basal to squamous cell carcinoma transitionSemantic proximity Read ↗

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and BeyondSemantic proximity Read ↗

Study protocol: Sonidegib for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome and EADO stage IIb Sporadic BCC, a phase II Study (SIBLINGS TRIAL).EU CT n. 2024-515989-14-00Semantic proximity Read ↗

Variable expression of Gorlin syndrome may reflect complexity of the signalling pathway.Semantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.Semantic proximity Read ↗

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Semantic proximity Read ↗

Nevoid basal cell carcinoma (Gorlin) syndrome.Semantic proximity Read ↗

The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for TreatmentSemantic proximity Read ↗

A Novel Case of Gorlin Syndrome Mosaicism Involving an SMO Gene Mutation: Clinical, Histological and Molecular Analysis of Basaloid Tumours.Semantic proximity Read ↗

SUFU ‐associated Gorlin syndrome: Expanding the spectrum between classic nevoid basal cell carcinoma syndrome and multiple hereditary infundibulocystic basal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.